Longevity pharmacology comes of age

Abstract

With a globally aging population, longevity is becoming the most promising market for the biotech industry. In animals, aging can be retarded and longevity extended, which, if translated to humans, would result in huge health benefits with remarkable commercial value. The potential to slow down human aging has led to a race to discover the most promising longevity drugs in animals and ultimately translate them to humans. Indeed, in recent years, there has been exponential growth in longevity drugs discovered in animal models. Investment in longevity biotech is also booming, and several clinical trials will soon shed light on which drugs extend healthy lives. Thus, the longevity pharmacology field promises to revolutionize the healthcare of a growing aging population.